Introduction
============

Angiosarcoma is a rare type of soft tissue sarcoma with the morphological and immunohistochemical features of endothelial cells. It accounts for 1--4% of all soft tissue sarcoma cases ([@b1-ol-0-0-6892],[@b2-ol-0-0-6892]). Angiosarcomas are a heterogeneous group of tumors. The primary sites of angiosarcoma include the skin, soft tissue and viscera. Clinical presentation varies considerably depending on the primary site; the majority of cutaneous angiosarcomas present as bruise-like patches, violaceous nodules or plaques, whereas angiosarcomas of soft tissue present as an enlarged painful mass. The clinical presentation of angiosarcoma of the viscera is variable, including abdominal pain, hepatosplenomegaly or anemia ([@b3-ol-0-0-6892]).

The prognosis for angiosarcoma is also associated with the primary site of the tumor. Fayette *et al* ([@b3-ol-0-0-6892]) retrospectively analyzed the clinicopathological features of 161 cases of angiosarcoma, and demonstrated that the patients\' survival was significantly impacted by the primary site. A primary site in the liver or heart was associated with a poor prognosis, whereas primary soft tissue tumors were associated with a relatively improved prognosis. Fury *et al* ([@b4-ol-0-0-6892]) identified that the progression-free survival time for scalp angiosarcoma was 6.8 months, whereas it was 2.8 months for sites below the clavicle. Due to the rarity of this tumor, the clinicopathological features and prognostic factors require further investigation. At present, there remains a lack of consensus on the treatment strategy for this rare type of tumor. Nevertheless, it is of paramount importance for pathologists to make an accurate diagnosis, as misdiagnosis may lead to inappropriate administration and incorrect assessment of the prognosis.

To better understand the clinicopathological features, treatment response and clinical outcomes of angiosarcoma, an analysis was performed on 200 consecutive cases, the largest series to date, with emphasis on defining the prognostic factors of this rare sarcoma.

Materials and methods
=====================

### Case selection

Between March 2006 and March 2014, 200 consecutive cases of angiosarcoma were identified from the consultation files and surgical pathology files of the Department of Pathology, Fudan University Shanghai Cancer Center, Fudan University (Shanghai, China). The present retrospective study was approved by The Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center. Written informed consent was obtained from the patients or guardians on behalf of the minors involved in the present study. Diagnosis of angiosarcoma was made according to the World Health Organization classification of Tumours of Soft Tissue and Bone ([@b5-ol-0-0-6892]). Clinical data, including age, sex, tumor location and size, therapy, pattern of recurrence, occurrence of metastasis, and clinical outcome, were obtained from the medical records, pathology reports or discharge summaries. The follow up information was measured via medical records and telephone interviews.

### Immunohistochemical staining

All specimens were fixed in 10% formalin and processed routinely for paraffin embedding. 4 µm-thick sections were cut and stained with hematoxylin and eosin. The diagnosis of each case was confirmed by two experienced pathologists and representative paraffin blocks containing tumor material were selected for immunohistochemical analysis. The sections were cut and deparaffinized according to standard histological techniques. Endogenous peroxidase activity was blocked by soaking the slides in 0.3% H~2~O~2~ in methanol for 30 min at 37°C. Antigen retrieval was performed by high pressure repair in 0.1 M citrate solution (pH 6.0) for 10 min, followed by incubation with the primary antibodies overnight at 4°C. The primary antibodies used in the study included cluster of differentiation (CD)31 (dilution 1:100; cat. no. JC70A; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), CD34 (dilution 1:100; cat. no. QBEnd 10; Dako; Agilent Technologies, Inc.), Friend leukemia virus integration 1 (FLI1; dilution 1:50; cat. no. MRQ-1; Beijing Zhongshan Jinqiao Biotechnology Co., Beijing, China), erythroblast transformation-specific-related gene (ERG; dilution 1:100; cat. no. EPR3864; Ventana Medical Systems, Tucson, AZ, USA), and cytokeratin (dilution 1:50; cat. no. M351501-2; Dako; Agilent Technologies, Inc.). Omission of primary antibody and substitution with non-specific immunoglobulins were used as negative controls. Appropriate positive controls were run concurrently for all antibodies tested. The slides were washed with PBS and incubated for 60 min at room temperature with a HRP-conjugated rabbit anti-mouse secondary antibody (dilution 1:200; cat. no. K0609; Agilent Technologies, Inc.). Following a further wash in PBS, the sections were stained with 0.05% diaminobenzidine containing 0.01% hydrogen peroxide. Finally, the sections were counterstained with hematoxylin, dehydrated and mounted. The immunohistochemical staining was observed with an optical microscope (BX43; Olympus Corp., Tokyo, Japan).

### Statistical analysis

The overall survival (OS) was defined as the length of time between the date of diagnosis of angiosarcoma and date of mortality by any cause or the last follow-up date. The disease-free survival (DFS) was defined as the interval between the date of diagnosis and the date of recurrence, metastases or mortality. The significance of differences between groups was calculated using a paired Student\'s t-tests or χ^2^ tests. Fisher\'s exact tests were used to conducted categorical variables presented as counts and percentages. Univariate analyses were performed using the Kaplan-Meier method, and the survival difference between groups was assessed using the log-rank test. Cox proportional hazards regression model was used for multivariate survival analysis. P\<0.05 was considered to indicate a statistically significant difference. SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze all data.

Results
=======

### Clinical characteristics

The head and neck (64 cases) were the most common primary sites, particularly the scalp. A total of 22 tumors occurred in the bone, and the 22 tumors occurring in the trunk included post mediastinum (4 cases), chest wall (2 cases), shoulder back (6 cases), abdominal cavity (2 cases), buttock (3 cases) and inguinal region (5 cases). A total of 15 tumors developed in the extremities. The spleen (14 cases), heart (10 cases), lung (6 cases) and liver (4 cases) were the most commonly involved internal organs. In contrast, 33 tumors occurred in a superficial organ, the breast. Other uncommon organs included the ovary (2 cases), adrenal gland (2 cases), ileum (1 case), colon (1 case), thyroid gland (1 case), dura matter (1 case) and penis (1 case). The origin of the primary site was not defined in 1 case. According to the tumor location, 200 cases were divided into four groups: i) Tumors involving the head and neck; ii) tumors involving breast; iii) tumors involving viscera (including internal organs and bone); and iv) tumors involving soft tissue (including trunk and extremities).

In total, 97 males and 103 females were included in the present study. The mean and median age was 52.2 and 53 years (range, 4--91 years), respectively. Clinical characteristics are summarized in [Table I](#tI-ol-0-0-6892){ref-type="table"}. Male preponderance was observed in cases occurring in the head and neck (male/female ratio: 2.2:1). In contrast, all the patients except 1 with primary breast angiosarcoma were females. However, the patients with angiosarcoma of solid organs and soft tissue exhibited a similar distribution between sexes. As demonstrated in [Table I](#tI-ol-0-0-6892){ref-type="table"}, a significantly increasing mean age was observed in patients with tumor of breast, viscera, soft tissue and head (P\<0.001). The peak incidence of angiosarcoma in the head and neck was in the sixth decade of life, while the peak age of incidences of breast angiosarcoma was younger compared with the peak ages in other sites.

The vast majority of head and neck angiosarcoma presented as bruise-like patches, violaceous nodules or plaques on the scalp in the present study. On progression, the lesions ulcerated and bled; patients complained of bleeding upon combing their hair. Satellite lesions were observed in certain patients. It has been reported that angiosarcoma of the head and neck in the elderly usually progresses slowly ([@b6-ol-0-0-6892]). In the present study, the interval between cutaneous lesion detection and tumor diagnosis was 1 month-40 years, with a median interval of 4.5 months. The most common symptom of angiosarcoma in soft tissue was an enlarged painful mass. Patients with primary breast angiosarcoma usually presented with a palpable mass, with rapid growth resulting in prominent enlargement of the involved breast and a bluish discoloration of the overlying skin. Patients with cardiac angiosarcoma or pulmonary angiosarcoma presented with dyspnea, cough or hemoptysis. The clinical presentation of angiosarcoma of viscera was rather variable, including abdominal pain, hepatosplenomegaly, anemia and even life-threatening hemorrhage. Pain was the most common clinical symptom of primary angiosarcoma of the bone.

There were 2 cases of post-radiation angiosarcoma included in the present study. One patient had received radiotherapy for nasopharynx cancer. Angiosarcoma developed in the radiation fields 35 years following the radiotherapy. The other patient exhibited a previous history of malignant lymphoma in the tongue root, and received radiotherapy. A total of 20 years following the radiotherapy, angiosarcoma was identified in the field of tongue root. A total of 3 cases of angiosarcoma of the extremities were associated with prolonged lymphedema (Stewart-Treves syndrome). A total of 2 patients developed upper limb angiosarcoma 10 and 14 years following radical mastectomy. The other patient with lower limb angiosarcoma exhibited a history of pain and swelling in the leg for 40 years. A history of 20--35 years of exposure to chemical products was noted in 6 patients. A total of 5 patients, including 2 patients with angiosarcoma involving the scalp, 2 patients with angiosarcoma involving the trunk and 1 patient with spleen angiosarcoma, exhibited a history of trauma. A total of 3 patients with breast angiosarcoma demonstrated a previous history of breast fibroadenoma, breast intraductal papilloma and thigh osteosarcoma, respectively. A total of 1 patient with a history of right breast human epidermal growth factor receptor 2-positive ductal adenocarcinoma was diagnosed with left breast angiosarcoma in the same year, and received modified radical mastectomy of the right breast and the extensive tumor resection of left breast, followed by Herceptin^®^ therapy. One patient with pleural mesothelioma developed pulmonary angiosarcoma 9 years later.

### Pathological features

Tumor size was recorded in 107 cases (mean, 5.2 cm; median, 4.5 cm; range, 0.5--15 cm). According to the degree of vascular differentiation, cellular pleomorphism and mitotic activity, all cases were divided into low grade, and high grade ([Table I](#tI-ol-0-0-6892){ref-type="table"}). In low-grade cases, tumors contained irregular, complex anastomosing channels lined by atypical endothelial cells ([Fig. 1A and B](#f1-ol-0-0-6892){ref-type="fig"}). In poorly differentiated areas, the high grade spindled tumor cells formed continuous sheets lacking vasoformation ([Fig. 1C](#f1-ol-0-0-6892){ref-type="fig"}). In the present study, 37 cases (18.5%, 37/200) exhibited an epithelioid appearance, and tumors were composed of epithelioid endothelial cells, which were classified as 'epithelioid angiosarcoma' and included in the high-grade group ([Fig. 1D](#f1-ol-0-0-6892){ref-type="fig"}). However, the epithelioid appearance was not observed in the angiosarcoma of breast, spleen, liver and heart ([Table I](#tI-ol-0-0-6892){ref-type="table"}).

Immunohistochemistry is important in confirming the diagnosis of angiosarcoma, particularly for poorly differentiated cases. CD31 protein was detected in 105/110 tested cases (95.5%) ([Fig. 2A and B](#f2-ol-0-0-6892){ref-type="fig"}). CD34 staining was positive in 73/102 tested cases (71.6%). ERG ([Fig. 2C and D](#f2-ol-0-0-6892){ref-type="fig"}) and FLI1 ([Fig. 2E and F](#f2-ol-0-0-6892){ref-type="fig"}), additional endothelial markers, demonstrated positive nuclear staining in all 20 tested cases. Cytokeratin was detected in 19/28 cases (67.9%) of the epithelioid angiosarcomas examined.

### Treatment

The therapeutic strategies of 123 patients were collected. According to the treatment modality, 123 patients were divided into two groups: i) 67 patients received non-multimodal treatment, including 64 patients treated with surgery alone, 2 patients treated with chemotherapy alone and 1 patient treated with radiotherapy alone; and ii) 56 patients received multidisciplinary treatment, including 33 patients treated with surgery and chemotherapy, 18 patients treated with surgery and radiotherapy, and 5 patients treated with a combination of surgery, radiotherapy and chemotherapy ([Table I](#tI-ol-0-0-6892){ref-type="table"}).

### Clinical follow-up

A total of 113 patients were followed up subsequent to angiosarcoma diagnosis until 31 March, 2014. The median follow-up duration was 13 months (range, 1--75 months). A total of 46 patients (40.7%) succumbed to the disease at a median interval of 10 months (range, 1--70 months), 31 patients (27.4%) lived with the disease at a median interval of 14 months (range, 1--61 months), and 34 patients (30.1%) lived with no evidence of the disease at a median interval of 22.5 months (range, 3--75 months). A total of 2 patients (1.8%) succumbed to hepatocellular carcinoma and lung adenocarcinoma. Tumor recurrence/metastasis was identified in 63 patients (55.8%) at a median interval of 4 months (range, 0--40 months). At initial diagnosis, 18 (15.9%) patients exhibited metastases. As summarized in [Table I](#tI-ol-0-0-6892){ref-type="table"}, bone (18 cases) and lung (18 cases) were the most common sites of tumor metastasis, followed by liver (8 cases), lymph nodes (8 cases), skin of the trunk (6 cases), parotid gland (4 cases), breast (3 cases), retroperitoneum (2 cases), pleura (1 case) and spleen (1 case). The parotid gland metastatic angiosarcomas originated exclusively from the head and neck, and the breast metastatic angiosarcomas originated exclusively from the contralateral breast.

In the present study, the median DFS and OS were 7, and 18 months, respectively. In all cases, the DFS at 1-, 3- and 5-years were 38.1, 22.1, and 19.3%, respectively. The OS at 1-, 3-, 5-years were 70.7, 50.0 and 40.8%, respectively. DFS and OS at 5-year in patients with tumors involving the head and neck, breast, viscera, and soft tissue are summarized in [Table I](#tI-ol-0-0-6892){ref-type="table"}. There was no marked difference between viscera and soft tissue groups in DFS, and OS. Therefore, the two groups were combined together for the survival analyses. Tumor location had a significant effect on DFS (P=0.032; [Fig. 3A](#f3-ol-0-0-6892){ref-type="fig"}) and OS (P\<0.001; [Fig. 3B](#f3-ol-0-0-6892){ref-type="fig"}). As demonstrated in [Fig. 3](#f3-ol-0-0-6892){ref-type="fig"}, the patients with primary breast angiosarcoma exhibited a significantly improved DFS and OS compared with the patients in the other two groups, while the patients with involvement of angiosarcoma in head and neck exhibited relatively poor prognoses.

Prognostic factors of survival by univariate analysis are summarized in [Table II](#tII-ol-0-0-6892){ref-type="table"}. Tumor size (≥5 cm) and tumor differentiation exhibited an effect on DFS (P=0.038 and \<0.001; [Fig. 3C and E](#f3-ol-0-0-6892){ref-type="fig"}, respectively) and OS (P=0.008 and \<0.001; [Fig. 3D and F](#f3-ol-0-0-6892){ref-type="fig"}, respectively). Tumor recurrence/metastasis was identified to be associated with DFS (P\<0.001), but was not associated with OS (P=0.284). Age (≥65 years) and treatment modality exhibited a significant effect on OS (P=0.003 and \<0.001, respectively), however, failed to predict DFS (P=0.172 and 0.447, respectively). Cox\'s analysis suggested that tumor recurrence/metastasis was an independent predictor of DFS \[Hazard ratio (HR), 9.299; 95% confidence interval (CI), 4.380--19.741; P\<0.001\] in patients with angiosarcoma, while tumor differentiation and treatment modality were the independent determinant of OS (HR, 8.439 and 2.672; 95% CI, 2.615--27.229 and 1.057--6.756; P\<0.001 and 0.038, respectively).

Discussion
==========

The aims of the present retrospective study were to describe the clinicopathological features and prognostic factors of 200 cases of angiosarcoma from a single Chinese medical institute. To the best of our knowledge, this series represents the largest study of this nature.

In accordance with previous studies, the head and neck (32.0%, 64/200) were the most common primary sites for angiosarcoma in the Chinese population, followed by the breast (16.5%, 33/200) ([@b3-ol-0-0-6892],[@b4-ol-0-0-6892],[@b7-ol-0-0-6892]--[@b9-ol-0-0-6892]). Soft tissue angiosarcoma (18.5%, 37/200), which was composed of angiosarcoma involving the trunk (11.0%, 22/200) and extremities (7.5%, 15/200), also represented a large proportion of angiosarcoma. However, a relatively high proportion of pulmonary angiosarcoma (3.0%, 6/200) was observed in this series. Lungs exhibit high frequencies of recurrence in patients with angiosarcoma ([@b9-ol-0-0-6892],[@b10-ol-0-0-6892]), and the incidence of primary pulmonary angiosarcoma was low; there are \<20 cases identified in English language literature at present ([@b11-ol-0-0-6892]). In the present study, the diagnosis of a primary pulmonary angiosarcoma was based on excluding the presence of neoplasms located in any other sites by thorough clinical and radiological examination including computed tomography (CT), magnetic resonance imaging or positron emission tomography-CT.

The results revealed in the present study suggest that angiosarcoma is a family of sarcomas with distinctive behavior depending on the primary site. According to the primary site, all the cases in the present study were divided into four groups: i) Head and neck; ii) breast; iii) viscera (including internal organ and bone); and iv) soft tissue (including trunk and extremities). Overall, angiosarcomas exhibited a similar distribution between sexes (female/male, 103/97; ratio, 1.1:1). However, male predominance was only be observed in patients with head and neck angiosarcoma, and almost all angiosarcoma of the breast occurred exclusively in women. A similar distribution between sexes was observed in patients with angiosarcomas of the viscera and soft tissue. The peak incidence of angiosarcoma was also different among the four groups. Concomitant with previous studies ([@b12-ol-0-0-6892],[@b13-ol-0-0-6892]), angiosarcoma involving the head and neck were more common in the 60--80 age group, while breast angiosarcoma was observed commonly in the 30--50 age group. The incidence of angiosarcoma involving viscera and soft tissue in the patient population of the present study was only observed in the 40--60 age group, which was younger compared with previous studies in which those aged 60--70 experienced the peak incidence rate ([@b14-ol-0-0-6892],[@b15-ol-0-0-6892]).

The results of the present study also demonstrated that the primary sites of the tumor affect the prognosis, which may be used to classify angiosarcoma. DFS and OS were affected by the primary site of angiosarcoma in the present study. The head and neck angiosarcomas were associated with the poorest survival, with a 5-year OS of 28.0%. However, the outcomes of patients with breast angiosarcomas in the present study were favorable, with a 5-year OS of 87.5%. Such a favorable outcome was not consistent with the other studies investigating breast angiosarcoma ([@b16-ol-0-0-6892],[@b17-ol-0-0-6892]). Angiosarcomas of the breast may arise *do novo*, and occur as secondary tumors following radiation ([@b18-ol-0-0-6892],[@b19-ol-0-0-6892]). The two types of breast angiosarcoma may be biologically different. Secondary breast angiosarcoma exhibits a poorer prognosis compared with the primary angiosarcoma ([@b20-ol-0-0-6892]). The prognosis of primary angiosarcoma is favorable, particularly with low-grade differentiation ([@b21-ol-0-0-6892]). In the present study, all of the breast angiosarcomas were primary and 30/33 tumors were low-grade, which may explain the favorable biological behavior of these tumors. Soft tissue angiosarcoma is rare, and little is known regarding its clinicopathological features and prognosis. The outcome of patients with soft tissue angiosarcoma lacks consensus in the literature. Meis-Kindblom and Kindblom ([@b14-ol-0-0-6892]) suggested that angiosarcoma of soft tissue is a high-grade sarcoma with high rate of mortality (53% of patients succumbed to the disease at a median interval of 11 months), while Fayette *et al* ([@b3-ol-0-0-6892]) demonstrated that the clinical outcome of soft tissue angiosarcoma was favorable (5-year survival rate, 74%), and visceral angiosarcoma was more aggressive and suggested poorer prognosis. However, in the present study, the 5-year OS rates of angiosarcoma, involving solid organs and soft tissue similar were 37.0 and 36.6%, respectively. Therefore, the clinicopathological features and prognosis of soft tissue, and viscera angiosarcoma require additional investigation.

Tumor size and tumor differentiation are important prognostic factors in soft tissue sarcoma ([@b22-ol-0-0-6892]), and their value in angiosarcoma may also be confirmed in the present study. The present univariate analysis confirmed that tumor size and histological grade are prognostic factors for DFS and OS. Tumors size ≥5 cm and high-grade histological differentiation predicted poor prognosis, as previously described ([@b7-ol-0-0-6892],[@b8-ol-0-0-6892],[@b10-ol-0-0-6892],[@b23-ol-0-0-6892],[@b24-ol-0-0-6892]). Other factors predicted poor clinical outcome, including old age (≥65 years) and tumor recurrence/metastasis. However, which prognostic factors were the most important was unclear. The present study identified that tumor differentiation and recurrence/metastasis were independent prognostic factors using multivariate survival analysis. Although certain parameters may not be independent prognostic factors, the present study hypothesizes that all the aforementioned factors mentioned should be considered by physicians when assessing the biological behavior of the tumor and choosing the therapeutic strategies.

At present, the treatment options for patients with angiosarcoma are controversial. The primary treatment of angiosarcoma was radical surgery with complete (R0) resection. Karpeh *et al* ([@b25-ol-0-0-6892]) suggested that the survival rate of patients with malignant of vascular tumors depends on R0 surgical resection. However, because of the invasive and multifocal nature of angiosarcoma, wide margins are difficult to achieve. Naka *et al* ([@b26-ol-0-0-6892]) indicated that multimodal treatment (surgery followed by chemotherapy and/or radiotherapy) was associated with improved survival. In the present study, patients were divided into two groups according to the mode of treatment: i) Non-multimodal treatment including surgery alone, which was the primary mode of simple treatment, chemotherapy alone and radiotherapy alone; and ii) multimodal treatment, including surgery followed by chemotherapy or radiotherapy, and a combination of surgery, chemotherapy and radiotherapy. The present multivariate analysis revealed that the multimodal treatment was an independent favorable prognostic factor in angiosarcoma.

The majority of angiosarcoma arises spontaneously, but several risk factors are associated with the development of angiosarcoma: Lymphoedema ([@b27-ol-0-0-6892]), radiation ([@b28-ol-0-0-6892]), various chemicals ([@b29-ol-0-0-6892],[@b30-ol-0-0-6892]) and immunodeficiency ([@b31-ol-0-0-6892]). In the present study, there were 2 cases of angiosarcoma arising at the radiation fields, which were considered radiation-associated angiosarcoma. Breast angiosarcoma, which was associated with radiotherapy for an epithelial breast cancer (secondary), comprised the majority of radiation-associated angiosarcoma ([@b32-ol-0-0-6892]). However, the 2 patients with radiation-associated angiosarcoma in the present study exhibited previous histories of nasopharynx cancer and malignant lymphoma, respectively, and all the cases of breast angiosarcoma were primary. Chronic lymphedema is an additional well-defined cause of angiosarcoma, which is known as Stewart-Treves syndrome. A total of 0.6--8.0% of all angiosarcoma have occurred under such conditions ([@b3-ol-0-0-6892],[@b33-ol-0-0-6892]). In the present study, 3 cases of angiosarcoma (1.5%) were associated with prolonged lymphedema. A total of 2 patients exhibited upper limb angiosarcoma arising from chronic lymphedema 10 and 14 years following radical mastectomy. The other patient with lower limb angiosarcoma exhibited a history of limb edema for 40 years.

In summary, angiosarcomas are a family of sarcomas with distinct clinical behavior depending on the primary sites, which effects the clinical outcome. Tumor recurrence/metastasis, tumor differentiation and treatment modality are the independent factors for prognosis. In the present study, multimodal treatment may improve the clinical outcome of patients with angiosarcoma.
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![Representative microscopic images of the appearance of angiosarcomas. Low grade angiosarcoma demonstrated (A) irregular, anastomosing vascular channels (hematoxylin and eosin staining, original magnification, ×200). (B) The ramifying channels were lined with atypical endothelial cells (hematoxylin and eosin staining, original magnification, ×400). (C) High grade angiosarcoma exhibiting proliferation of high grade spindle tumor cells without clear vasoformation (hematoxylin and eosin staining, original magnification, ×400). (D) High grade angiosarcoma with epithelioid appearance with abundant amphophilic to lightly eosinophilic cytoplasm (hematoxylin and eosin staining, original magnification, ×400).](ol-14-05-5370-g00){#f1-ol-0-0-6892}

![Immunohistochemical features of angiosarcoma. Tumor cells stained positively for the cluster of differentiation 31 antibody with (A) hematoxylin and eosin staining; and (B) immunohistochemical staining, original magnification, ×100. Nuclear erythroblast transformation-specific-related gene staining with (C) hematoxylin and eosin staining; and (D) immunohistochemical staining, original magnification, ×100, and Friend leukemia virus integration 1 staining with (E) hematoxylin and eosin staining; and (F) immunohistochemical staining, original magnification, ×200 were positive in tumor cells.](ol-14-05-5370-g01){#f2-ol-0-0-6892}

![Kaplan-Meier curves comparing DFS and OS. (A) DFS and (B) OS of patients with different tumor location. (C) DFS and (D) OS of patients with different tumor sizes. (E) DFS and (F) OS of patients with different tumor differentiation. DFS, disease free survival; OS, overall survival.](ol-14-05-5370-g02){#f3-ol-0-0-6892}

###### 

Clinicopathological features of 200 patients with angiosarcoma.

  Clinicopathological features              Total (n=200)   Viscera (n=65)   Head and neck (n=64)   Soft tissue (n=37)   Breast (n=33)
  ----------------------------------------- --------------- ---------------- ---------------------- -------------------- ---------------
  Male/female                               97/103          32/33            44/20                  20/17                1/32
  Mean age, years                           52.3            45.5             66.0                   52.6                 38.6
    \<65                                    137             55               25                     25                   31
    ≥65                                     63              10               39                     12                   2
  Mean size, cm                             5.2             6.4              4.5                    4.6                  5.1
    \<5                                     57              12               15                     18                   12
    ≥5                                      50              19               13                     9                    9
    Unknown                                 93              34               36                     10                   12
  Tumor differentiation                                                                                                  
    High grade                              94              29               42                     20                   3
    Low grade                               106             36               22                     17                   30
  Epithelioid appearance                    37              14               10                     13                   0
  Tumor recurrence/metastasis                                                                                            
    Yes                                     63              21               14                     16                   12
    No                                      50              15               15                     9                    11
    Unknown                                 87              29               35                     12                   20
  Metastatic site                                                                                                        
    Bone                                    18              11               3                      3                    1
    Lung                                    18              5                2                      9                    2
    Liver                                   8               6                2                      0                    0
    Lymph node                              8               4                2                      2                    0
    Trunk                                   6               0                0                      2                    4
    Parotid gland                           4               0                4                      0                    0
    Breast                                  3               0                0                      0                    3
    Retroperitoneum                         2               2                0                      0                    0
    Pleura                                  1               1                0                      0                    0
    Spleen                                  1               1                0                      0                    0
  Treatment modality                                                                                                     
    Multimodal therapy                      56              18               11                     13                   14
    Surgery + radiotherapy                  18              5                5                      4                    4
    Surgery + chemotherapy                  33              12               5                      9                    7
    Surgery + radiotherapy + chemotherapy   5               1                1                      0                    3
    Non-multimodal therapy                  67              22               20                     14                   11
    Surgery                                 64              21               18                     14                   11
    Radiotherapy                            2               1                1                      0                    0
    Chemotherapy                            1               0                1                      0                    0
    Unknown                                 77              25               33                     10                   8
  Survival, %                                                                                                            
    5-year disease-free survival            19.3            19.0             0                      18.7                 34.8
    5-year overall survival                 40.8            37.0             28.0                   36.6                 87.5

###### 

Univariate analysis of prognostic factors for survival.

                                Disease-free survival rate   Overall survival rate             
  ----------------------------- ---------------------------- ----------------------- --------- ------
  Age, years                    0.172                                                0.003     
    \<65                                                     21.4                              54.8
    ≥65                                                      0                                 0
  Tumor size, cm                0.038                                                0.008     
    \<5                                                      38.9                              51.7
    ≥5                                                       5.6                               31.6
  Tumor differentiation         \<0.001                                              \<0.001   
    High grade                                               0                                 11.3
    Low grade                                                36.9                              86.9
  Tumor location                0.032                                                \<0.001   
    Head and neck                                            0                                 28.0
    Viscera and soft tissue                                  18.9                              31.1
    Breast                                                   34.8                              87.5
  Treatment modality            0.447                                                \<0.001   
    Multimodal therapy                                       19.0                              53.5
    Non-multimodal therapy                                   21.7                              31.7
  Tumor recurrence/metastasis   \<0.001                                              0.284     
    Yes                                                      0                                 31.0
    No                                                       60.4                              58.9

[^1]: Contributed equally
